Literature DB >> 2294436

Deletions of interferon genes in acute lymphoblastic leukemia.

M O Diaz1, C M Rubin, A Harden, S Ziemin, R A Larson, M M Le Beau, J D Rowley.   

Abstract

Structural rearrangements involving the short arm of chromosome 9, including bands 9p21 and 22, are found in the leukemia cells of 7 to 13 percent of patients with acute lymphoblastic leukemia. The interferon-alpha gene cluster and the interferon-beta 1 gene have been localized to this chromosomal region. We have previously demonstrated deletions of these genes in several cell lines established in vitro from patients with lymphoblastic leukemia. We report here homozygous or hemizygous deletions of the interferon-alpha and interferon-beta 1 genes in samples of leukemia cells from patients with lymphoblastic leukemia. Of 62 patients examined, 18 (29 percent) had such deletions. Four patients (7 percent) had homozygous deletions of the interferon-alpha gene cluster; of these, one also had a homozygous deletion and three had hemizygous deletions of the interferon-beta 1 gene. Fourteen patients (23 percent) had hemizygous deletions of both the interferon-alpha gene cluster and the interferon-beta 1 gene. In 8 of the 18 patients with deletions, the deletions of interferon genes were submicroscopic; in the 11 other patients, chromosomal rearrangements of 9p, including translocations or deletions, were visible on light microscopy. These chromosomal and molecular deletions are likely to be related to the loss of a tumor-suppressor gene (or genes) located on 9p, which may be an interferon gene or an unrelated but closely linked gene.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2294436     DOI: 10.1056/NEJM199001113220202

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  29 in total

Review 1.  Haematology.

Authors:  N T O'Connor
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

2.  Collateral Lethality: A new therapeutic strategy in oncology.

Authors:  Florian L Muller; Elisa A Aquilanti; Ronald A DePinho
Journal:  Trends Cancer       Date:  2015-11-01

3.  Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers.

Authors:  T Nobori; K Takabayashi; P Tran; L Orvis; A Batova; A L Yu; D A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

4.  Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines.

Authors:  H M Pomykala; S K Bohlander; P L Broeker; O I Olopade; M O Díaz
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

Review 5.  Progress against cancer.

Authors:  S Broder; J E Karp
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  Characterization of three monoclonal antibodies that recognize the interferon alpha 2 receptor.

Authors:  O R Colamonici; F D'Alessandro; M O Diaz; S A Gregory; L M Neckers; R Nordan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 7.  Interferon-alpha in childhood haematological malignancies.

Authors:  R Simkó; K Nagy
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

Review 8.  Interferons and their stimulated genes in the tumor microenvironment.

Authors:  Hyeonjoo Cheon; Ernest C Borden; George R Stark
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

Review 9.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

10.  Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours.

Authors:  J Mora; M Alaminos; C de Torres; P Illei; J Qin; N-K V Cheung; W L Gerald
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.